CytoSorbents, Aferetica Launch Organ Perfusion System In Italy

• CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy) have launched products to remove inflammatory mediators at Italy's European Society of Organ Transplantation Congress.

• Aferetica's PerLife ex vivo organ perfusion system and CytoSorbents' PerSorb adsorber are based on the CytoSorbents ECOS-300CY sorbent technology.

• PerLife is a system for an organ transplant that provides both perfusion and purification of the kidney and the liver, following organ retrieval and before organ implantation.

• CytoSorbents' PerSorb perfusion cartridge is used to remove inflammatory mediators that can compromise the health and quality of the organs.

• Related: CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag

• Price Action: CTSO shares are up 4.08% at $9.44 during the market session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• FDA Gives 510(K) Nod To Vapotherm's Next-Gen High-Velocity Therapy

• Lantern Pharma's LP-184 Receives Orphan Drug Tag For Brain Cancer Indication

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.